1 July 2023 in Disease Models & Mechanisms
As early as in the acute phase of the coronavirus disease 2019 (COVID-19) pandemic, the research community voiced concerns about the long-term implications of infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), like many other viruses, can trigger chronic disorders that last months or even years. Long COVID, the chronic and persistent disorder lasting more than 12 weeks after the primary infection with SARS-CoV-2, involves a variable number of neurological manifestations, ranging from mild to severe and even fatal. In vitro and in vivo modeling suggest that SARS-CoV-2 infection drives changes within neurons, glia and the brain vasculature. In this Review, we summarize the current understanding of the neuropathology of acute and long COVID, with particular emphasis on the knowledge derived from brain organoid models. We highlight the advantages and main limitations of brain organoids, leveraging their human-derived origin, their similarity in cellular and tissue architecture to human tissues, and their potential to decipher the pathophysiology of long COVID.
16 February 2026 in bioRxiv
While SARS-CoV-2 primarily targets the respiratory system, its neurological effects have become a significant clinical concern. Postmortem analyses reveal astrogliosis, neuronal death, and blood-brain barrier dysfunction, yet the interplay between neural injury and endogenous repair remains unclear. Here, we employed human embryonic stem cell–derived brain organoids to examine viral tropism, bystander effects, and regenerative responses following infection. Single-cell transcriptomics and histological assays showed that SARS-CoV-2 productively infects neurons, neural progenitors, astroglia, and choroid plexus cells, triggering widespread apoptosis and senescence in both infected and neighboring cells. Despite low infection rates, organoids activated robust regenerative programs, including axon guidance, Wnt pathway signaling in mature neurons, and radial glia proliferation. Importantly, macrophage migration inhibitory factor (MIF) emerged as a key mediator, being strongly upregulated in both infected and uninfected cells, particularly in the choroid plexus. Recombinant MIF promoted dendritic outgrowth and cortical progenitor activation in uninfected organoids. Computational analyses indicated that MIF stimulates neural regenerative via EGFR signaling and upregulates its own expression in non-infected cells. These findings identify MIF as a molecular link between SARS-CoV-2-induced neural damage and regenerative activation in cortical cells.
10 August 2026 in Cellular and Molecular Neurobiology
Neurological complications are among typical clinical manifestations, both during the acute phase of SARS-CoV-2 infection and long-term post-acute COVID-19 sequelae, i.e., Long COVID. A growing body of evidence connects SARS-CoV-2 infection to systemic inflammation, peripheral immune dysregulation, functional alteration of the blood–brain barrier (BBB), neuroinflammatory processes, mitochondrial dysfunction and pathological protein aggregation, all of which are central to the pathogenesis of major neurodegenerative diseases. In this review, we discuss the converging shared underlying molecular mechanisms that link the ‘acute’ SARS-CoV-2 infection that often only lasts for days and ‘chronic’ neurodegenerative diseases that often take decades to develop. We further review human induced pluripotent stem cells (iPSCs)-derived brain organoid and BBB models for Parkinson’s disease (PD) and Alzheimer’s disease (AD) as well as artificial intelligence (AI)-facilitated knowledge graph methods that are used to hypothesize and validate the potential mechanistic links. We propose that besides the established links between viral infections and neurodegenerative or neuroinflammatory conditions, such as Epstein-Barr virus (EBV) in multiple sclerosis or herpes zoster in AD, SARS-CoV-2 infection might be another important factor driving the future burden of the most common neurodegenerative diseases. Graphical Abstract Schematic illustrating the potential link between the progression from SARS-CoV-2 infection and immune dysregulation to the development of Long COVID and eventually the subsequent onset of major neurodegenerative diseases (e.g., Parkinson's disease and Alzheimer's disease).
19 August 2025 in bioRxiv
Summary: COVID-19 is increasingly recognized as a potential trigger or accelerator of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. To systematically explore the putative molecular and clinical associations between them, we present CBM KG (Causal Biological Mechanisms Knowledge Graph)—a manually curated, comorbidity-centric resource developed within the EU-funded COMMUTE project. CBM KG integrates over 2,800 cause-and-effect or correlative relationships from 63 peer-reviewed publications, highlighting key mechanisms such as viral entry routes, blood-brain barrier alteration, microglial activation, neuroinflammation, and APOE ε4-associated susceptibility. Each relationship in the graph is fully traceable to its source evidence, ensuring transparency and reproducibility. Unlike general-purpose or single disease-focused knowledge graphs, CBM KG is specifically designed to represent causal biological mechanisms spanning both infectious and neurodegenerative processes. By encoding directional, cause-and-effect relationships, it supports the interpretation of clinical co-occurrences through plausible mechanistic links between overlapping disease pathways, offering high-resolution insights at both molecular and clinical levels. Availability and implementation: The BEL files, Neo4j database, and Cytoscape visualization files are publicly available at: https://github.com/SCAI-BIO/CBM-Comorbidity-KG .
10 March 2026 in SSRN Electronic Journal
Background: Neurological complications are among typical clinical manifestations, both during the acute phase of SARS-CoV-2 infection and long-term post-acute COVID-19 sequelae, i.e., Long COVID. A growing body of evidence connects SARS-CoV-2 infection to systemic inflammation, peripheral immune dysregulation, blood-brain barrier (BBB) dysfunction, neuroinflammatory processes, mitochondrial dysfunction and pathological protein aggregation, all of which are central to the pathogenesis of major neurodegenerative diseases. Main Body: In this review, we discuss the converging shared underlying molecular mechanisms that link the ‘acute’ SARS-CoV-2 infection that often only lasts for days and ‘chronic’ neurodegenerative diseases that often take decades to develop. We further review human induced pluripotent stem cells (iPSCs)-derived brain organoid and BBB models for Parkinson’s disease (PD) and Alzheimer’s disease (AD) as well as artificial intelligence (AI)-facilitated knowledge graph methods that are used to hypothesize, discover and validate the potential mechanistic links. Conclusions: We suggest that besides the established links between viral infections and neurodegenerative or neuroinflammatory conditions, such as Epstein-Barr virus (EBV) in multiple sclerosis or herpes zoster in AD, SARS-CoV-2 infection is another important factor defining the future burden of the most common neurodegenerative diseases.